Zenas BioPharma, Inc./$ZBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Ticker
$ZBIO
Sector
Primary listing
Employees
130
Headquarters
Website
ZBIO Metrics
BasicAdvanced
$713M
-
-$5.31
-
-
Price and volume
Market cap
$713M
52-week high
$18.24
52-week low
$6.11
Average daily volume
158K
Financial strength
Current ratio
5.233
Quick ratio
5.157
Long term debt to equity
0.09
Total debt to equity
0.421
Profitability
EBITDA (TTM)
-188.997
Gross margin (TTM)
-970.86%
Net profit margin (TTM)
-1,180.05%
Operating margin (TTM)
-1,260.67%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-47.94%
Return on equity (TTM)
-88.40%
Valuation
Price to revenue (TTM)
37.624
Price to book
2.97
Price to tangible book (TTM)
2.97
Price to free cash flow (TTM)
-3.8
Free cash flow yield (TTM)
-26.31%
Free cash flow per share (TTM)
-4.455
Growth
Revenue change (TTM)
-70.00%
Earnings per share change (TTM)
-90.50%
ZBIO News
AllArticlesVideos
Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)
Accesswire·2 months ago
June 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky
Accesswire·2 months ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zenas BioPharma, Inc. stock?
Zenas BioPharma, Inc. (ZBIO) has a market cap of $713M as of August 23, 2025.
What is the P/E ratio for Zenas BioPharma, Inc. stock?
The price to earnings (P/E) ratio for Zenas BioPharma, Inc. (ZBIO) stock is 0 as of August 23, 2025.
Does Zenas BioPharma, Inc. stock pay dividends?
No, Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Zenas BioPharma, Inc. dividend payment date?
Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. (ZBIO) does not currently have a Beta indicator.